Safety of Rivaroxaban For Prophylaxis Vein Thrombosis Post Total Hip and Knee Replacement
DOI:
https://doi.org/10.47701/icohetech.v5i1.4193Keywords:
bleeding, total hip and knee replacement, rivaroxabanAbstract
Orthopaedic surgery such as surgery on the pelvis and knee bones has a high risk of developing Deep Vein Thromoembolism (DVT), especially in patients with hypercoagulability. Venous thromboembolism is the main cause of morbidity and mortality in orthopedic patients that can be prevented using thromboprophylaxis, but on the other hand is related to the risk of bleeding side effects. The study aimed to evaluate the safety of oral Rivaroxaban prophylaxis in patients after Total Hip and Knee Replacement. This research applied cross sectional technique. Retrospective data were taken from the medical records of Dr. Moewardi Surakarta, period January 2023- July 2024. The data taken are secondary data from the patient's medical record by recording clinical symptoms that appear. Rivaroxaban safety evaluation includes the incidence rate of bleeding as well as the factors that influence the occurrence of bleeding. A total of 38 patients met the inclusion criteria of the study. Bleeding occurred in 4 cases (10.5%). Factors that affect the incidence of bleeding renal failure (p = 0.001). Monitoring of Rivaroxaban side effects is indispensable. Pharmaceuticals can play an important role in monitoring and preventing the occurrence of bleeding by paying attention to risk factors, especially kidney failure.
References
WHO.|||UNTRANSLATED_CONTENT_START|||Osteoarthritis.|||UNTRANSLATED_CONTENT_END|||World Health [Internet] 2013,12(Osteoarthritis in Priority Medicines for Europe and the World 2013 Update):6-8. Available at http://www.who.int/medicines/areas/priority_medicines/Cho
Soeroso J, Isbagio H, Kalim H, Broto R, Pramudiyo R. Osteoarthritis. Buku ajar ilmu penyakit dalam. V. Jakarta: Internal Publishing, 2009. pp.2538-48.
Anderson, David R., Dunbar, Michael, Murnaghan, John, Kahn, Susan R., Gross, Peter, Forsythe, Michael, Pelet, Stephane, Fisher, William, Belzile, Etienne, Dolan, Sean, Crowther, Mark, Bohm, Eric, MacDonald, Steven J., Gofton, Wade, Kim, Paul, Zukor, David, Pleasance, Susan, Andreou, Pantelis, Doucette, Steve, Theriault, Chris, Abianui, Abongnwen, Carrier, Marc, Kovacs, Michael J., Rodger, Marc A., Coyle, Doug, Wells, Philip S., & Vendittoli, Pascal Andre. (2018). Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. The New England Journal of Medicine, 378(8), 699–707. https://doi.org/10.1056/NEJMoa1712746
Cools, Frank, Johnson, Dana, Camm, Alan J., Bassand, Jean Pierre, Verheugt, Freek W. A., Yang, Shu, Tsiatis, Anastasios, Fitzmaurice, David A., Goldhaber, Samuel Z., Kayani, Gloria, Goto, Shinya, Haas, Sylvia, Misselwitz, Frank, Turpie, Alexander G. G., Fox, Keith A. A., Pieper, Karen S., & Kakkar, Ajay K. (2021). Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry. Journal of Thrombosis and Haemostasis : JTH, 19(9), 2322–2334. https://doi.org/10.1111/jth.15415
Dahal, Khagendra, Kunwar, Sumit, Rijal, Jharendra, Schulman, Peter, & Lee, Juyong. (2016). Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest, 149(4), 951–959. https://doi.org/10.1378/chest.15-1719
Dong, Junling, Wang, Fajun, & Sundararajan, Sophia. (2020). Use of Dual Antiplatelet Therapy Following Ischemic Stroke. Stroke, 51(5), e78–e80. https://doi.org/10.1161/STROKEAHA.119.028400
Falck-Ytter, Yngve, Francis, Charles W., Johanson, Norman A., Curley, Catherine, Dahl, Ola E., Schulman, Sam, Ortel, Thomas L., Pauker, Stephen G., & Colwell, Clifford W. Jr. (2012). Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e278S-e325S. https://doi.org/10.1378/chest.11-2404
Frisullo, Giovanni, Profice, Paolo, Brunetti, Valerio, Scala, Irene, Bellavia, Simone, Broccolini, Aldobrando, Caliandro, Pietro, Di Iorio, Riccardo, Morosetti, Roberta, Pilato, Fabio, Laborante, Renzo, & Della Marca, Giacomo. (2020). Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study). Brain Sciences, 11(1). https://doi.org/10.3390/brainsci11010030
Heidari, Behzad. (2011). Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Caspian Journal of Internal Medicine, 2(2), 205–212.
Hillarp, A., Baghaei, F., Fagerberg Blixter, I., Gustafsson, K. M., Stigendal, L., Sten-Linder, M., Strandberg, K., & Lindahl, T. L. (2011). Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. Journal of Thrombosis and Haemostasis : JTH, 9(1), 133–139. https://doi.org/10.1111/j.1538-
Kjerpeseth, Lars J., Selmer, Randi, Ariansen, Inger, Karlstad, Øystein, Ellekjær, Hanne, & Skovlund, Eva. (2019). Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. PloS One, 14(8), e0221500. https://doi.org/10.1371/journal.pone.0221500
Linn, Sarah, Murtaugh, Bryan, & Casey, Ellen. (2012). Role of sex hormones in the development of osteoarthritis. PM & R : The Journal of Injury, Function, and Rehabilitation, 4(5 Suppl), S169-73. https://doi.org/10.1016/j.pmrj.2012.01.013
Litwic, Anna, Edwards, Mark H., Dennison, Elaine M., & Cooper, Cyrus. (2013). Epidemiology and burden of osteoarthritis. British Medical Bulletin, 105, 185–199. https://doi.org/10.1093/bmb/lds038
Mueck, Wolfgang, Schwers, Stephan, & Stampfuss, Jan. (2013). Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thrombosis Journal, 11(1), 10. https://doi.org/10.1186/1477-9560-11-10
Paciaroni, Maurizio, Agnelli, Giancarlo, Caso, Valeria, et al. (2017). Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. Journal of the American Heart Association, 6(12). https://doi.org/10.1161/JAHA.117.007034
Piel-Julian, M. L., Mahévas, M., Germain, J., Languille, L., Comont, T., Lapeyre-Mestre, M., Payrastre, B., Beyne-Rauzy, O., Michel, M., Godeau, B., Adoue, D., & Moulis, G. (2018). Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. Journal of Thrombosis and Haemostasis : JTH, 16(9), 1830–1842. https://doi.org/10.1111/jth.14227
Plotnikoff, Ronald, Karunamuni, Nandini, Lytvyak, Ellina, Penfold, Christopher, Schopflocher, Donald, Imayama, Ikuyo, Johnson, Steven T., & Raine, Kim. (2015). Osteoarthritis prevalence and modifiable factors: a population study. BMC Public Health, 15, 1195. https://doi.org/10.1186/s12889-015-2529-0
Rönn, Karolin, Reischl, Nikolaus, Gautier, Emanuel, & Jacobi, Matthias. (2011). Current surgical treatment of knee osteoarthritis. Arthritis, 2011, 454873. https://doi.org/10.1155/2011/454873
Samare Fekri, Mitra, Khalily Zade, Mahdie, & Fatehi, Shima. (2014). The association of deep vein thrombosis with cancer treatment modality: chemotherapy or surgery? Iranian Red Crescent Medical Journal, 16(9), e14722. https://doi.org/10.5812/ircmj.14722
Schulman, S., & Kearon, C. (2005). Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis : JTH, 3(4), 692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.x
Senoo, Keitaro, Lane, Deirdre, & Lip, Gregory Yh. (2014). Stroke and bleeding risk in atrial fibrillation. Korean Circulation Journal, 44(5), 281–290. https://doi.org/10.4070/kcj.2014.44.5.281
Shireman, T. I., Howard, P. A., Kresowik, T. F., & Gami, Apoor S. (2005). Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation. Evidence-Based Medicine, 10(2), 56. https://doi.org/10.1136/ebm.10.2.56
So, Charlotte H., & Eckman, Mark H. (2017). Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 43(1), 7–17. https://doi.org/10.1007/s11239-016-1425-5
Wang, Huijie, Rosendaal, Frits R., Cushman, Mary, & van Hylckama Vlieg, Astrid. (2022). Association between cardiovascular risk factors and venous thromboembolism in the elderly. Research and Practice in Thrombosis and Haemostasis, 6(2), e12671. https://doi.org/10.1002/rth2.12671
Yasaka, Masahiro, Minematsu, Kazuo, Toyoda, Kazunori, Mori, Etsuro, Hirano, Teruyuki, Hamasaki, Toshimitsu, Yamagami, Hiroshi, Nagao, Takehiko, Yoshimura, Shinichi, & Uchiyama, Shinichiro. (2019). Rivaroxaban administration after acute ischemic stroke: The RELAXED study. PloS One, 14(2), e0212354. https://doi.org/10.1371/journal.pone.0212354
